Related Experiment Video
Updated: Jul 27, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Nateglinide (Starlix): update on a new antidiabetic agent
1Division of Endocrinology/Metabolism, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
International Journal of Clinical Practice
|August 16, 2003
Summary
Nateglinide effectively manages postprandial hyperglycemia by stimulating glucose-dependent insulin release. This oral antidiabetic agent offers a low risk of hypoglycemia, making it suitable for various patient groups.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) management requires targeting both fasting and postprandial hyperglycemia.
- Current oral antidiabetic agents have varying mechanisms of action and safety profiles.
- Postprandial hyperglycemia contributes significantly to overall glycemic burden and long-term complications.
Purpose of the Study:
- To evaluate the efficacy and safety of nateglinide, a novel oral antidiabetic agent.
- To assess nateglinide's role in managing postprandial hyperglycemia.
- To determine nateglinide's suitability in specific patient populations.
Main Methods:
- Nateglinide administration before meals.
- Assessment of insulin release in a glucose-dependent manner.
- Evaluation of HbA1c reduction in monotherapy and combination therapy.
Main Results:
- Nateglinide stimulates prompt, glucose-dependent insulin release with short duration of action.
- Effective targeting of postprandial hyperglycemia with low risk of hypoglycemia.
- Comparable HbA1c reduction (-0.5 to -1.5%) to other oral antidiabetic agents in monotherapy.
- Additive glycemic control when combined with metformin.
Conclusions:
- Nateglinide is a safe and effective option for managing postprandial hyperglycemia.
- Its favorable profile makes it suitable for treatment-naive patients, elderly individuals, and those with renal or mild hepatic impairment.
- Nateglinide offers a valuable therapeutic option for patients experiencing hypoglycemia with sulfonylureas or inadequate control with other agents.
Related Concept Videos
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...